Jonas Willmann, MD

Current classifications of OMD assign one state per patient. But within the same patient, lesions respond, persist, and progress on divergent paths.
We propose metastatic trajectories – a lesion-level framework to guide local + systemic therapy in metastatic NSCLC.
📄 @JCO_ASCO

🚨 Out now in @RO_GreenJournal: our @ESTRO_RT guideline on high-dose thoracic reirradiation for NSCLC.

International expert recommendations for patient selection, staging, target delineation, dose/fractionation, cumulative OAR assessment, and systemic therapy integration.

Explainable AI for global oncology policy 🔍🌍

Key takeaway: radiotherapy capacity + UHC expansion repeatedly emerge as high-impact drivers of cancer outcomes

‼️ Higher total health spending alone may be insufficient without strategic allocation.

@militspatel @EChrisDee

🚀 Can SBRT alone be used to treat oligometastatic cancer—allowing selected patients to defer systemic therapy?

Our meta-analysis, now published in @JAMANetworkOpen, evaluates systemic therapy–free survival after SBRT without upfront systemic therapy.

Re-irradiating recurrent NSCLC is challenging due to high cumulative OAR dose. Our automated non-coplanar planning approach reduces critical exposure while maintaining coverage ➜ safer thoracic re-RT 🔄🎯

doi.org/10.1016/j.phro…

@RadOncUSZ @Unispital_USZ #radonc